The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%
Protocol Amendment History
71 amendments
This ClinicalTrials.gov record has been amended 71 times since 2019-05-30; most recent amendment 2025-11-18.
Status change: Recruiting → Active, Not Recruiting2025-11-18
Status change: Not Yet Recruiting → Recruiting2020-02-19